Constantinos O'MAhony

Constantinos O'MAhony

Auto-generated profile, based on publicly available information

Constantinos O'MAhony

Barts Health NHS Trust, London, United Kingdom

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2014 in European Heart Journal
Verified
Journal Article
Open access
PDF file
Perry ElliottPerry Elliott
Perry Elliott
AAAris Anastasakis
Aris Anastasakis
MBMichael Borger
Michael Borger
MBMartin Borggrefe
Martin Borggrefe
FCFranco Cecchi
Franco Cecchi
NSNeha Sekhri
Neha Sekhri
Guidelines summarize and evaluate all available evidence at the time of the writing process, on a particular issue with the aim of assisting health professionals in selecting the best management strategies for an individual patient, with a given condition, taking into account the impact on outcome, as well as the risk-benefit-ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help the health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

14 October 2013 in European Heart Journal
Verified
Journal Article
Open access
PDF file
COConstantinos O'Mahony
Constantinos O'Mahony
FJFatima Jichi
Fatima Jichi
MPMenelaos Pavlou
Menelaos Pavlou
LMLorenzo Monserrat
Lorenzo Monserrat
AAAristides Anastasakis
Aristides Anastasakis
FIfor the Hypertrophic Cardiomyopathy Outcomes Investigators
for the Hypertrophic Cardiomyopathy Outcomes Investigators
Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death (SCD) in young adults. Current risk algorithms provide only a crude estimate of risk and fail to account for the different effect size of individual risk factors. The aim of this study was to develop and validate a new SCD risk prediction model that provides individualized risk estimates. The prognostic model was derived from a retrospective, multi-centre longitudinal cohort study. The model was developed from the entire data set using the Cox proportional hazards model and internally validated using bootstrapping. The cohort consisted of 3675 consecutive patients from six centres. During a follow-up period of 24 313 patient-years (median 5.7 years), 198 patients (5%) died suddenly or had an appropriate implantable cardioverter defibrillator (ICD) shock. Of eight pre-specified predictors, age, maximal left ventricular wall thickness, left atrial diameter, left ventricular outflow tract gradient, family history of SCD, non-sustained ventricular tachycardia, and unexplained syncope were associated with SCD/appropriate ICD shock at the 15% significance level. These predictors were included in the final model to estimate individual probabilities of SCD at 5 years. The calibration slope was 0.91 (95% CI: 0.74, 1.08), C-index was 0.70 (95% CI: 0.68, 0.72), and D-statistic was 1.07 (95% CI: 0.81, 1.32). For every 16 ICDs implanted in patients with ≥4% 5-year SCD risk, potentially 1 patient will be saved from SCD at 5 years. A second model with the data set split into independent development and validation cohorts had very similar estimates of coefficients and performance when externally validated. This is the first validated SCD risk prediction model for patients with HCM and provides accurate individualized estimates for the probability of SCD using readily collected clinical parameters.

7 September 2013 in Heart
Verified
Journal Article
Closed access
PDF file
OGOliver P Guttmann
Oliver P Guttmann
MRM Shafiqur Rahman
M Shafiqur Rahman
COConstantinos O'MAhony
Constantinos O'MAhony
AAAris Anastasakis
Aris Anastasakis
Perry ElliottPerry Elliott
Perry Elliott
Context: HCM is commonly associated with AF. Current guidelines for AF management omit detailed advice for HCM because of a lack of clinical prediction tools that estimate the risk of developing AF and an absence of adequately powered treatment studies. Objective: To critically review current literature on atrial fibrillation (AF) and thromboembolism in hypertrophic cardiomyopathy (HCM) and meta-analyse prevalence and incidence. Data Sources: PubMed and Web of Science. Study Selection: Studies investigating AF and stroke in HCM as primary or secondary endpoint. Data Extraction: Two investigators independently reviewed and extracted data from the identified articles. A random effect meta-regression model and I2 statistics were used for analysis. Results: A population of 7381 patients (33 studies) revealed overall AF prevalence of 22.45% (95% CI 20.13% to 24.77%), I2=78.9% (p<0.001). Overall prevalence of thromboembolism in HCM patients with AF was 27.09% (95% CI 20.94% to 33.25%), I2=61.4% ( p<0.01). Overall AF incidence was 3.08% per 100 patients per year (95% CI 2.63% to 3.54%, I2=86.5%, p<0.001) and incidence of thromboembolism in HCM patients with AF was 3.75% per 100 patients per year (95% CI 2.88% to 4.61%), I2=37.9% (p=0.1). Left atrial (LA) dimension and age were common predictors for AF and thromboembolism. Meta-analysis revealed an LA diameter of 38.03 mm (95% CI 34.62% to 41.44%) in sinus rhythm and 45.37 mm (95% CI 41.64% to 49.04%) in AF. There were no randomised controlled trials of therapy; anticoagulation was associated with lower stroke incidence but data on other interventions were limited and contradictory. Conclusions: AF is common in HCM and associated with high thromboembolic risk. LA dimension and age are independently associated with AF but the literature is insufficient to create robust clinical tools to predict AF or thromboembolism. Most data suggest that AF patients should be anticoagulated.

1 September 2019 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
GNGabrielle Norrish
Gabrielle Norrish
TDTao Ding
Tao Ding
EFElla Field
Ella Field
Lidia ZiolkowskaLidia Ziolkowska
Lidia Ziolkowska
IOIacopo Olivotto
Iacopo Olivotto
Juan Pablo KaskiJuan Pablo Kaski
Juan Pablo Kaski
Sudden cardiac death (SCD) is the most common mode of death outside of infancy in childhood hypertrophic cardiomyopathy (HCM),1,2 with higher annual rates compared with those in adults with the disease.3 Current practice guidelines recommend primary prevention implantable cardioverter defibrillators (ICDs) in children based on the presence of clinical risk factors for SCD extrapolated mostly from observational adult studies,4,5 but this approach poorly discriminates risk in both adult and pediatric populations.6,7 A clinical risk tool (HCM Risk-SCD) that estimates the 5-year risk of SCD was developed8 and validated in adults with HCM.9-12 The aim of this study was to develop a similar pediatric SCD risk model using a large, international cohort and compare its performance with the adult model.

6 March 2018 in Circulation
Verified
Journal Article
Closed access
COConstantinos O’mahony
Constantinos O’mahony
FJFatima Jichi
Fatima Jichi
SOSteve R. Ommen
Steve R. Ommen
ICImke Christiaans
Imke Christiaans
EAEloisa Arbustini
Eloisa Arbustini
Perry ElliottPerry Elliott
Perry Elliott
Background: Identification of people with hypertrophic cardiomyopathy (HCM) who are at risk of sudden cardiac death (SCD) and require a prophylactic implantable cardioverter defibrillator is challenging. In 2014, the European Society of Cardiology proposed a new risk stratification method based on a risk prediction model (HCM Risk-SCD) that estimates the 5-year risk of SCD. The aim was to externally validate the 2014 European Society of Cardiology recommendations in a geographically diverse cohort of patients recruited from the United States, Europe, the Middle East, and Asia. Methods: This was an observational, retrospective, longitudinal cohort study. Results: The cohort consisted of 3703 patients. Seventy three (2%) patients reached the SCD end point within 5 years of follow-up (5-year incidence, 2.4% [95% confidence interval {CI}, 1.9–3.0]). The validation study revealed a calibration slope of 1.02 (95% CI, 0.93–1.12), C-index of 0.70 (95% CI, 0.68–0.72), and D-statistic of 1.17 (95% CI, 1.05–1.29). In a complete case analysis (n= 2147; 44 SCD end points at 5 years), patients with a predicted 5-year risk of <4% (n=1524; 71%) had an observed 5-year SCD incidence of 1.4% (95% CI, 0.8–2.2); patients with a predicted risk of ≥6% (n=297; 14%) had an observed SCD incidence of 8.9% (95% CI, 5.96–13.1) at 5 years. For every 13 (297/23) implantable cardioverter defibrillator implantations in patients with an estimated 5-year SCD risk ≥6%, 1 patient can potentially be saved from SCD. Conclusions: This study confirms that the HCM Risk-SCD model provides accurate prognostic information that can be used to target implantable cardioverter defibrillator therapy in patients at the highest risk of SCD.

28 October 2014 in Heart
Verified
Journal Article
Open access
PDF file
LLLuis R Lopes
Luis R Lopes
PSPetros Syrris
Petros Syrris
OGOliver P Guttmann
Oliver P Guttmann
COConstantinos O'MAhony
Constantinos O'MAhony
HTHak Chiaw Tang
Hak Chiaw Tang
Perry ElliottPerry Elliott
Perry Elliott
Objective: A predictable relation between genotype and disease expression is needed in order to use genetic testing for clinical decision-making in hypertrophic cardiomyopathy (HCM). The primary aims of this study were to examine the phenotypes associated with sarcomere protein (SP) gene mutations and test the hypothesis that variation in non-sarcomere genes modifies the phenotype. Methods: Unrelated and consecutive patients were clinically evaluated and prospectively followed in a specialist clinic. High-throughput sequencing was used to analyse 41 genes implicated in inherited cardiac conditions. Variants in SP and non-SP genes were tested for associations with phenotype and survival. Results: 874 patients (49.6±15.4 years, 67.8% men) were studied; likely disease-causing SP gene variants were detected in 383 (43.8%). Patients with SP variants were characterised by younger age and higher prevalence of family history of HCM, family history of sudden cardiac death, asymmetric septal hypertrophy, greater maximum LV wall thickness (all p values<0.0005) and an increased incidence of cardiovascular death (p=0.012). Similar associations were observed for individual SP genes. Patients with ANK2 variants had greater maximum wall thickness (p=0.0005). Associations at a lower level of significance were demonstrated with variation in other non-SP genes. Conclusions: Patients with HCM caused by rare SP variants differ with respect to age at presentation, family history of the disease, morphology and survival from patients without SP variants. Novel associations for SP genes are reported and, for the first time, we demonstrate possible influence of variation in non-SP genes associated with other forms of cardiomyopathy and arrhythmia syndromes on the clinical phenotype of HCM.